The purpose of this study is to evaluate whether fostamatinib is safe and effective in the treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
26
Fostamatinib 150 mg bid. The dose of Fostamatinib may be reduced at any time to as low as 100 mg PO once daily (qd) if dose limiting adverse events are observed.
Hemoglobin response
Hemoglobin level of \> 10 g/dL and 2 g/dL higher than the baseline hemoglobin
Time frame: by Week 24
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States
Arizona Oncology Associates, PC
Tucson, Arizona, United States
UC San Diego Moores Cancer Center
La Jolla, California, United States
Loma Linda University Cancer Center
Loma Linda, California, United States
LAC/USC Health Center
Los Angeles, California, United States
University of California at San Francisco
San Francisco, California, United States
The Oncology Institute of Hope and Innovation
Whittier, California, United States
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, United States
Mid-Florida Hematology & Oncology Centers, P.A.
Orange City, Florida, United States
Montgomery Cancer Center
Mount Sterling, Kentucky, United States
...and 26 more locations